LncRNA HCP5 remodels G6PD dual post-translational modification to mediate metabolic adaptations driving osimertinib resistance in lung adenocarcinoma
{{output}}
Introduction: Osimertinib represents the standard treatment for EGFR-mutant lung adenocarcinoma (LUAD); however, acquired resistance limits its clinical efficacy. Elucidating the underlying mechanisms of resistance is crucial for... ...
